Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Fate Therapeutics Inc shares valued at $11,275 were sold by TAHL CINDY on Jan 09 ’26. At $1.06 per share, TAHL CINDY sold 10,589 shares. The insider’s holdings dropped to 387,081 shares worth approximately $0.41 million following the completion of this transaction.
Also, Valamehr Bahram sold 5,190 shares, netting a total of over 5,557 in proceeds. Following the sale of shares at $1.07 each, the insider now holds 329,708 shares.
Before that, TAHL CINDY had added 10,589 shares to its account. In a trade valued at $11,275, the Officer bought Fate Therapeutics Inc shares for $1.06 each.
As published in a research note from H.C. Wainwright on October 31, 2025, Fate Therapeutics Inc [FATE] has been rated up from a Neutral to a Buy and the price target has been revised to $5. Analysts at Wedbush upgraded the stock from ‘”a Neutral”‘ to ‘”an Outperform”‘ outlook in a report released in late October. As of November 18, 2024, BofA Securities has increased its “an Underperform” rating to a “Neutral” for FATE. Earlier on June 17, 2024, Piper Sandler upgraded its rating. Their new recommendation was “an Overweight” for FATE stock which previously was a “a Neutral”.
Analyzing FATE Stock Performance
On last trading session, Fate Therapeutics Inc [NASDAQ: FATE] plunged -2.78% to $1.05. The stock’s lowest price that day was $1.03, but it reached a high of $1.085 in the same session. During the last five days, there has been a drop of approximately -0.94%. Over the course of the year, Fate Therapeutics Inc shares have dropped approximately -16.33%.
Support And Resistance Levels for Fate Therapeutics Inc (FATE)
RSI (Relative Strength Index) is 49.71 on the 14-day chart, showing neutral technical sentiment.
Is Fate Therapeutics Inc subject to short interest?
Stocks of Fate Therapeutics Inc saw a sharp rise in short interest on 2025-12-31 jumping by 1.88 million shares to 10.07 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 8.18 million shares. A jump of 18.68% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 7.4 of the overall float, the days-to-cover ratio (short ratio) jumped to 7.4.
Which companies own the most shares of Fate Therapeutics Inc (FATE)?
In terms of Fate Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 7.5 in the next 12 months, up nearly 594.44% from the previous closing price of $1.08. Analysts anticipate Fate Therapeutics Inc stock to reach 145 by 2026, with the lowest price target being 3. In spite of this, 8 analysts ranked Fate Therapeutics Inc stock as Buy at the end of 2026. On March 27, 2023, Wells Fargo assigned a price target of “an Equal weight” to the stock and resumed coverage with a $6.
